Gilead SciencesGILD
About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 17,600
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
196% more first-time investments, than exits
New positions opened: 275 | Existing positions closed: 93
56% more funds holding in top 10
Funds holding in top 10: 18 [Q3] → 28 (+10) [Q4]
14% more capital invested
Capital invested by funds: $85.7B [Q3] → $98.2B (+$12.4B) [Q4]
9% more funds holding
Funds holding: 1,692 [Q3] → 1,837 (+145) [Q4]
2.93% more ownership
Funds ownership: 82.21% [Q3] → 85.14% (+2.93%) [Q4]
10% less call options, than puts
Call options by funds: $864M | Put options by funds: $959M
11% less repeat investments, than reductions
Existing positions increased: 634 | Existing positions reduced: 709
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
JP Morgan Chris Schott 29% 1-year accuracy 5 / 17 met price target | 24%upside $130 | Overweight Maintained | 27 Mar 2025 |
Morgan Stanley Matthew Harrison 38% 1-year accuracy 9 / 24 met price target | 24%upside $130 | Overweight Maintained | 11 Mar 2025 |
B of A Securities Tim Anderson 40% 1-year accuracy 6 / 15 met price target | 21%upside $126 | Buy Maintained | 5 Mar 2025 |
Wells Fargo Mohit Bansal 26% 1-year accuracy 7 / 27 met price target | 34%upside $140 | Overweight Maintained | 5 Mar 2025 |
Oppenheimer Hartaj Singh 21% 1-year accuracy 4 / 19 met price target | 26%upside $132 | Outperform Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 32 articles about GILD published over the past 30 days
